Bavarian Nordic Price (BAVA.CO)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

78,324,444

(2.1039)%

Bavarian Performance History

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respirator... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $143.4-300
  • Market Cap 13.08B
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Dr. Paul John Chaplin MSc, Ph.D.
  • IPO Date: January, 03, 2000
  • Country: DK
  • Currency: DKK
  • Headquaters: No Data
  • Employees: 1605

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation